NeuroPace (NASDAQ:NPCE) crossed a major financial threshold in 2025, reporting preliminary full-year revenue of approximately $100 million as its brain-responsive neurostimulation technology gains traction as a standard of care for drug-resistant epilepsy.
The Mountain View, California-based company saw total revenue climb 25% for the year, driven by a robust fourth quarter that generated $26.6 million.
The core of this growth remains the RNS® System, which saw revenue jump 26% in the final three months of the year to $22.4 million.
This momentum reflects a strategic pivot by management to focus exclusively on high-margin, personalized neuromodulation after winding down its third-party distribution business earlier in the year.
The RNS System remains the only FDA-approved "closed-loop" platform that targets epilepsy by continuously monitoring brain activity and delivering therapeutic pulses in real-time to intercept seizures at their source.
Looking ahead to 2026, the company expects core RNS revenue to grow between 20% and 22%.
This guidance does not yet include potential contributions from Idiopathic Generalized Epilepsy (IGE), an indication expansion currently under FDA review.